Antibacterials/mogamulizumab

Antibacterials/mogamulizumab Reactions 1680, p34 - 2 Dec 2017 Mogamulizumab-induced cutaneous adverse reactions: 6 case reports In a study involving medical review of 25 patients, six patients (3 women and 3 men) aged 44–67 years developed cutaneous adverse reactions during treatment with mogamulizumab. Of these, four patients also received cefepime, cefozopran or piperacillin/tazobactam, which also contributed to the development of mogamulizumab-induced cutaneous adverse reactions (MCARs) [dosages and routes not stated; not all outcomes stated]. All the six patients, who were diagnosed with adult T-cell leukaemia/lymphoma, received treatment with mogamulizumab. After 22–129 days, and after 2-8 cycles of the mogamulizumab therapy, the patients developed grade 2–3 MCARs. Before onsets of MCARs, four out of these six patients started receiving antibacterial therapy with cefepime (2 patients), cefepime and piperacillin/tazobactam (1 patient) and cefozopran (1 patient) for febrile neutropenia. Within two days after the initiation of the antibacterial therapy, the patients developed MCARs. Subsequent immunohistochemical studies of the biopsy specimens revealed multiple CD8+T-cells. The patients were treated with topical/systemic steroids and antihistamines. The mogamulizumab therapy was not discontinued in any of the patient, however, the antibacterial therapy was discontinued in four patients. Within a week after discontinuation of the antibacterial therapy, the skin reaction improved in these four patients. Author comment: "Table 1 summarises the characteristics of 6 patients (25%) who experienced MCARs." "We suspected that drug hypersensitivities were involved in a significant proportion of MCARs." "Given this, the administration of antibiotics was strongly suspected to contribute to MCAR occurrence in 4 patients (cases 2, 3, 4, and 6)." Yasu T, et al. Hypersensitivity reaction to beta-lactam antibiotics in patients with adult t-cell leukemia/lymphoma treated with mogamulizumab. International Journal of Clinical Pharmacology and Therapeutics 55: 807-810, No. 10, Jan 2017. Available from: URL: http://doi.org/10.5414/CP203066 - Japan 803284042 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antibacterials/mogamulizumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/antibacterials-mogamulizumab-B3cxIQNDAq
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38965-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p34 - 2 Dec 2017 Mogamulizumab-induced cutaneous adverse reactions: 6 case reports In a study involving medical review of 25 patients, six patients (3 women and 3 men) aged 44–67 years developed cutaneous adverse reactions during treatment with mogamulizumab. Of these, four patients also received cefepime, cefozopran or piperacillin/tazobactam, which also contributed to the development of mogamulizumab-induced cutaneous adverse reactions (MCARs) [dosages and routes not stated; not all outcomes stated]. All the six patients, who were diagnosed with adult T-cell leukaemia/lymphoma, received treatment with mogamulizumab. After 22–129 days, and after 2-8 cycles of the mogamulizumab therapy, the patients developed grade 2–3 MCARs. Before onsets of MCARs, four out of these six patients started receiving antibacterial therapy with cefepime (2 patients), cefepime and piperacillin/tazobactam (1 patient) and cefozopran (1 patient) for febrile neutropenia. Within two days after the initiation of the antibacterial therapy, the patients developed MCARs. Subsequent immunohistochemical studies of the biopsy specimens revealed multiple CD8+T-cells. The patients were treated with topical/systemic steroids and antihistamines. The mogamulizumab therapy was not discontinued in any of the patient, however, the antibacterial therapy was discontinued in four patients. Within a week after discontinuation of the antibacterial therapy, the skin reaction improved in these four patients. Author comment: "Table 1 summarises the characteristics of 6 patients (25%) who experienced MCARs." "We suspected that drug hypersensitivities were involved in a significant proportion of MCARs." "Given this, the administration of antibiotics was strongly suspected to contribute to MCAR occurrence in 4 patients (cases 2, 3, 4, and 6)." Yasu T, et al. Hypersensitivity reaction to beta-lactam antibiotics in patients with adult t-cell leukemia/lymphoma treated with mogamulizumab. International Journal of Clinical Pharmacology and Therapeutics 55: 807-810, No. 10, Jan 2017. Available from: URL: http://doi.org/10.5414/CP203066 - Japan 803284042 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off